{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:57:51Z","timestamp":1787007471152,"version":"build-2736575974"},"reference-count":34,"publisher":"Knowledge E DMCC","issue":"9","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["knepublishing.com"],"crossmark-restriction":true},"short-container-title":["IJRM"],"abstract":"<jats:p>Background: Heart diseases affect 1\u20134% of pregnancies, leading to fetomaternal complications. Brain natriuretic peptide is a key biomarker for assessing cardiac adaptation to pregnancy-related hemodynamic changes. The longer half-life of its terminal fragment, N terminal pro brain natriuretic peptide (NT-ProBNP), increases its diagnostic utility.\r\nObjective: This study aimed to evaluate the association between NT-proBNP serum levels and fetomaternal complications in pregnant women with cardiovascular disease.\r\nMaterials and Methods: A prospective longitudinal study was conducted at the Cardiology and Obstetrics Clinic of Imam Reza hospital, Mashhad, Iran, from July 2019-July 2020. 50 pregnant women in their third trimester with cardiovascular disease (New York Heart Association class 2 or higher) were included. Based on NT-proBNP levels, participants were categorized into normal (n = 37) and elevated (n = 13) groups using a 125 pg\/ml cutoff. Fetomaternal complications were assessed and analyzed.\r\nResults: Elevated NT-proBNP levels were significantly associated with increased hypertension in the second (p = 0.05) and third (p &lt; 0.0001) visits and low Apgar scores (p = 0.05). A significant difference in drug history (p = 0.013) was observed between the groups. However, no significant differences were found in other variables, including intensive care unit)\/neonatal intensive care unit admission, mode of delivery, electrocardiography findings, or echocardiographic results (p &gt; 0.05).\r\nConclusion: Elevated NT-proBNP levels are strongly linked to hypertension during pregnancy and low neonatal Apgar scores, highlighting its potential as a predictive biomarker for fetomaternal risk assessment.<\/jats:p>","DOI":"10.18502\/ijrm.v23i9.20162","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:21:49Z","timestamp":1762003309000},"page":"749-758","update-policy":"https:\/\/doi.org\/10.18502\/knecrossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["N-terminal pro-B-type natriuretic peptide levels in pregnant women with heart disease and complications: A cohort study"],"prefix":"10.18502","volume":"23","author":[{"given":"Zahra","family":"Hatamian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Seyede Houra Mousavi Vahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farveh","family":"Vakilian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoorak","family":"Poorzand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzieh","family":"Lotfalizade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Zirak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan Mehrad","family":"Majd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzieh","family":"Nozari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salmeh","family":"Dadgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malihe","family":"Afiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7770","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"key":"307961","doi-asserted-by":"crossref","unstructured":"[1] Ramlakhan KP, Johnson MR, Roos-Hesselink JW. Pregnancy and cardiovascular disease. Nat Rev Cardiol 2020; 17: 718\u2013731.","DOI":"10.1038\/s41569-020-0390-z"},{"key":"307962","doi-asserted-by":"crossref","unstructured":"[2] Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstr\u00f6m-Lundqvist C, Cifkova R, De Bonis M, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy: The task force for the management of cardiovascular diseases during pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2018; 39: 3165\u20133241.","DOI":"10.1093\/eurheartj\/ehy478"},{"key":"307963","doi-asserted-by":"crossref","unstructured":"[3] Pfaller B, Sathananthan G, Grewal J, Mason J, D\u2019Souza R, Spears D, et al. Preventing complications in pregnant women with cardiac disease. J Am Coll Cardiol 2020; 75: 1443\u20131452.","DOI":"10.1016\/j.jacc.2020.01.039"},{"key":"307964","doi-asserted-by":"crossref","unstructured":"[4] Gongora MC, Wenger NK. Cardiovascular complications of pregnancy. Int J Mol Sci 2015; 16: 23905\u201323928.","DOI":"10.3390\/ijms161023905"},{"key":"307965","doi-asserted-by":"crossref","unstructured":"[5] Madamanchi C, Alhosaini H, Sumida A, Runge MS. Obesity and natriuretic peptides, BNP and NT-proBNP: Mechanisms and diagnostic implications for heart failure. Int J Cardiol 2014; 176: 611\u2013617.","DOI":"10.1016\/j.ijcard.2014.08.007"},{"key":"307966","doi-asserted-by":"crossref","unstructured":"[6] Alawieh H, El Chemaly T, Alam S, Khraiche M. Towards point-of-care heart failure diagnostic platforms: BNP and NT-proBNP biosensors. Sensors 2019; 19: 5003.","DOI":"10.3390\/s19225003"},{"key":"307967","doi-asserted-by":"crossref","unstructured":"[7] Shah KB, Nolan MM, Rao K, Wang DJ, Christenson RH, Shanholtz CB, et al. The characteristics and prognostic importance of NT-ProBNP concentrations in critically ill patients. Am J Med 2007; 120: 1071\u20131077.","DOI":"10.1016\/j.amjmed.2007.07.032"},{"key":"307968","doi-asserted-by":"crossref","unstructured":"[8] Januzzi Jr JL, Zannad F, Anker SD, Butler J, Filippatos G, Pocock SJ, et al. Prognostic importance of NT-proBNP and effect of empagliflozin in the EMPEROR-reduced trial. J Am Coll Cardiol 2021; 78: 1321\u20131332.","DOI":"10.1016\/j.jacc.2021.07.046"},{"key":"307969","doi-asserted-by":"crossref","unstructured":"[9] Drewniak W, Szybka W, Bielecki D, Malinowski M, Kotlarska J, Krol-Jaskulska A, et al. Prognostic significance of NT-proBNP levels in patients over 65 presenting acute myocardial infarction treated Invasively or conservatively. BioMed Res Int 2015; 2015: 782026.","DOI":"10.1155\/2015\/782026"},{"key":"307970","unstructured":"[10] Arekhi S, Ghodsi A, Omranzadeh A, Rahimi HR. Does adaptive T cell immunity have any role in the pathophysiology and histopathology of Buerger\u2019s disease? J Basic Res Med Sci 2021; 8: 1\u20139."},{"key":"307971","doi-asserted-by":"crossref","unstructured":"[11] Aimo A, Januzzi Jr JL, Mueller C, Mir\u00f2 O, Figal DAP, Jacob J, et al. Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure. Int J Cardiol 2019; 293: 137\u2013142.","DOI":"10.1016\/j.ijcard.2019.06.005"},{"key":"307972","doi-asserted-by":"crossref","unstructured":"[12] Papageorgiou N, Provid\u00eancia R, Falconer D, Wongwarawipat T, Tousoulis D, Lim WY, et al. Predictive role of BNP\/NT-proBNP in non-heart failure patients undergoing catheter ablation for atrial fibrillation: An updated systematic review. Curr Med Chem 2020; 27: 4469\u20134478.","DOI":"10.2174\/0929867326666191213095554"},{"key":"307973","doi-asserted-by":"crossref","unstructured":"[13] Hauspurg A, Marsh D, Catov J. NT-proBNP in early pregnancy and future hypertension -more explorations needed- reply. JAMA Cardiology 2022; 7: 989\u2013990.","DOI":"10.1001\/jamacardio.2022.2003"},{"key":"307974","doi-asserted-by":"crossref","unstructured":"[14] Ker JA, Soma-Pillay P. NT-proBNP: When is it useful in obstetric medicine? Obstet Med 2018; 11: 3\u20135.","DOI":"10.1177\/1753495X17736717"},{"key":"307975","doi-asserted-by":"crossref","unstructured":"[15] Bredy Ch, Ministeri M, Kempny A, Alonso-Gonzalez R, Swan L, Uebing A, et al. New York Heart Association (NYHA) classification in adults with congenital heart disease: Relation to objective measures of exercise and outcome. Eur Heart J Qual Care Clin Outcomes 2018; 4: 51\u201358.","DOI":"10.1093\/ehjqcco\/qcx031"},{"key":"307976","doi-asserted-by":"crossref","unstructured":"[16] Cabo Fustaret MC, Escobar A, Illia R, Uranga Imaz M, Rivas C, Lobenstein G, et al. NT-Pro-BNP: Correlation with adverse outcome markers in hypertensive gestational syndromes. Pregnancy Hypertens 2013; 3: 85.","DOI":"10.1016\/j.preghy.2013.04.077"},{"key":"307977","unstructured":"[17] Doust J, Lehman R, Glasziou P. The role of BNP testing in heart failure. Am Fam Physician 2006; 74: 1893\u20131900."},{"key":"307978","unstructured":"[18] Novack ML, Zubair M. Natriuretic peptide B type test. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020."},{"key":"307979","doi-asserted-by":"crossref","unstructured":"[19] Ghomian N, Vakilian F, Shahri B, Rostaminejad V, Khadem-Rezaiyan M. Can brain natriuretic peptide predict cardiovascular complications in severe preeclampsia? A case-control study. Int J Reprod BioMed 2019; 17: 271\u2013278.","DOI":"10.18502\/ijrm.v17i4.4552"},{"key":"307980","doi-asserted-by":"crossref","unstructured":"[20] Yousif D, Bellos I, Penzlin AI, Hijazi MM, Illigens BM-W, Pinter A, et al. Autonomic dysfunction in preeclampsia: A systematic review. Front Neurol 2019; 10: 816.","DOI":"10.3389\/fneur.2019.00816"},{"key":"307981","doi-asserted-by":"crossref","unstructured":"[21] Liu HH, Cao YX, Jin JL, Guo YL, Zhu CG, Wu NQ, et al. Prognostic value of NT-proBNP in patients with chronic coronary syndrome and normal left ventricular systolic function according to glucose status: A prospective cohort study. Cardiovasc Diabetol 2021; 20: 84.","DOI":"10.1186\/s12933-021-01271-0"},{"key":"307982","doi-asserted-by":"crossref","unstructured":"[22] Rudolf H, M\u00fcgge A, Trampisch HJ, Scharnagl H, M\u00e4rz W, Kara K. NT-proBNP for risk prediction of cardiovascular events and all-cause mortality: The getABI-study. Int J Cardiol Heart Vasc 2020; 29: 100553.","DOI":"10.1016\/j.ijcha.2020.100553"},{"key":"307983","doi-asserted-by":"crossref","unstructured":"[23] Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655\u2013663.","DOI":"10.1056\/NEJMoa031994"},{"key":"307984","doi-asserted-by":"crossref","unstructured":"[24] Di Angelantonio E, Chowdhury R, Sarwar N. B-type natriuretic peptides and cardiovascular risk: Systematic review and meta-analysis of 40 prospective studies. Circulation 2009; 120: 2177\u20132187.","DOI":"10.1161\/CIRCULATIONAHA.109.884866"},{"key":"307985","doi-asserted-by":"crossref","unstructured":"[25] Sadlecki P, Grabiec M, Walentowicz-Sadlecka M. Prenatal clinical assessment of NT-proBNP as a diagnostic tool for preeclampsia, gestational hypertension and gestational diabetes mellitus. PLoS One 2016; 11: e0162957.","DOI":"10.1371\/journal.pone.0162957"},{"key":"307986","doi-asserted-by":"crossref","unstructured":"[26] Nguyen TX, Van Tri Nguyen HNN, Phan BBH. Serum levels of NT-Pro BNP in patients with preeclampsia. Integr Blood Press Control 2022; 15: 43.","DOI":"10.2147\/IBPC.S360584"},{"key":"307987","doi-asserted-by":"crossref","unstructured":"[27] Bakacak M, Serin S, Ercan O, K\u00f6st\u00fc B, Bakacak Z, Kiran H. Association of serum N-terminal pro-brain natriuretic peptide levels with the severity of preeclampsia. J Matern Fetal Neonatal Med 2016; 29: 2802\u20132806.","DOI":"10.3109\/14767058.2015.1104663"},{"key":"307988","doi-asserted-by":"crossref","unstructured":"[28] Siegmund A, Pieper P, Bouma B, Rosenberg F, Groen H, Bilardo C, et al. Early N-terminal pro-B-type natriuretic peptide is associated with cardiac complications and function during pregnancy in congenital heart disease. Neth Heart J 2021; 29: 262\u2013272.","DOI":"10.1007\/s12471-021-01540-3"},{"key":"307989","doi-asserted-by":"crossref","unstructured":"[29] Averina M, Stylidis M, Brox J, Schirmer H. NT-ProBNP and high-sensitivity troponin T as screening tests for subclinical chronic heart failure in a general population. ESC Heart Fail 2022; 9: 1954\u20131962.","DOI":"10.1002\/ehf2.13906"},{"key":"307990","doi-asserted-by":"crossref","unstructured":"[30] Panagopoulou V, Deftereos S, Kossyvakis C, Raisakis K, Giannopoulos G, Bouras G, et al. NTproBNP: An important biomarker in cardiac diseases. Curr Top Med Chem 2013; 13: 82\u201394.","DOI":"10.2174\/1568026611313020002"},{"key":"307991","doi-asserted-by":"crossref","unstructured":"[31] \u00c1lvarez-Fern\u00e1ndez I, Prieto B, Rodr\u00edguez V, Ruano Y, Escudero AI, \u00c1lvarez FV. N-terminal pro B-type natriuretic peptide and angiogenic biomarkers in the prognosis of adverse outcomes in women with suspected preeclampsia. Clin Chim Acta 2016; 463: 150\u2013157.","DOI":"10.1016\/j.cca.2016.10.033"},{"key":"307992","doi-asserted-by":"crossref","unstructured":"[32] Tanous D, Siu SC, Mason J, Greutmann M, Wald RM, Parker JD, et al. B-type natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol 2010; 56: 1247\u20131253.","DOI":"10.1016\/j.jacc.2010.02.076"},{"key":"307993","unstructured":"[33] Zhang Y, Tan X, Yu F. The diagnostic and predictive values of N-terminal pro-B-type natriuretic peptides in pregnancy complications and neonatal outcomes. Am J Translat Res 2021; 13: 10372."},{"key":"307994","doi-asserted-by":"crossref","unstructured":"[34] Sheikh M, Ostadrahimi P, Salarzaei M, Parooie F. Cardiac complications in pregnancy: A systematic review and meta-analysis of diagnostic accuracy of BNP and N-Terminal Pro-BNP. Cardiol Ther 2021; 10: 501\u2013514.","DOI":"10.1007\/s40119-021-00230-w"}],"container-title":["International Journal of Reproductive BioMedicine (IJRM)"],"original-title":[],"link":[{"URL":"https:\/\/knepublishing.com\/index.php\/ijrm\/article\/download\/20162\/30783","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/knepublishing.com\/index.php\/ijrm\/article\/download\/20162\/30783","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:43:12Z","timestamp":1762004592000},"score":1,"resource":{"primary":{"URL":"https:\/\/knepublishing.com\/index.php\/ijrm\/article\/view\/20162"},"secondary":[{"URL":"http:\/\/ijrm.ir\/article-1-3152-en.html","label":"UNIVERSITY"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.18502\/ijrm.v23i9.20162","relation":{},"ISSN":["2476-3772","2476-4108"],"issn-type":[{"value":"2476-3772","type":"electronic"},{"value":"2476-4108","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}